Agios Pharmaceuticals, Inc. - AGIO Total Company Value-to-Revenue Ratio

Agios Pharmaceuticals management has pivoted its strategy toward rare genetic pathologies, divesting its oncology business to fund research and development. The GURU.Markets portal displays the EV/Sales multiple, where 7928.50 shows the current value of the metric. Revenues rely on sales of an anemia drug, creating a cash generator. However, high dependence on a narrow portfolio and pricing regulation in the US create certain risks.
Agios - analytical breakdowns and key metrics (AGIO)

This indicator compares the total enterprise value, adjusted for net debt, against annual sales to determine the asset's market premium. By analyzing the EV/Revenue multiple, an investor can see how the patents of Agios Pharmaceuticals (AGIO) in the field of rare genetic diseases allow the market to value the company with a high multiple premium due to the absence of direct competition.